Baseline tumor assessments: correlation with response to single-agent pembrolizumab
| . | PMR∗, N = 11†,‡ . | Near-CMR§, N = 8† . | CMR‖, N = 11† . | P value¶ . |
|---|---|---|---|---|
| Stage | .6 | |||
| Early | 5 (45) | 4 (50) | 3 (27) | |
| Advanced | 6 (55) | 4 (50) | 8 (73) | |
| Epstein-Barr virus–encoded small RNAs | .3 | |||
| Negative | 7 (88) | 5 (83) | 4 (50) | |
| Positive | 1 (12) | 1 (17) | 4 (50) | |
| Missing | 3 | 2 | 3 | |
| 9p24.1 Alterations | .4 | |||
| Polysomy or copy gain | 4 (36) | 5 (71) | 5 (50) | |
| Amplification by ratio# | 7 (64) | 2 (29) | 5 (50) | |
| Missing | 0 | 1 | 1 | |
| Percent of residual disomic HRS cells | 0.0 (0.0-0.4) | 0.1 (0.0-0.9) | 0.0 (0.0-0.5) | .4 |
| Missing | 0 | 1 | 1 | |
| Percent of HRS cells with polysomy or CNG | 0.8 (0.2-1.0) | 0.9 (0.1-1.0) | 0.9 (0.5-1.0) | .9 |
| Missing | 0 | 1 | 1 | |
| Percent of HRS cells with amplification by ratio# | 0.0 (0.0-0.8) | 0.0 (0.0-0.1) | 0.0 (0.0-0.3) | .3 |
| Missing | 0 | 1 | 1 | |
| PD-L1 H score | 213.0 (122.0-300.0) | 211.5 (20.0-300.0) | 221.5 (62.0-300.0) | >.9 |
| Missing | 0 | 0 | 1 | |
| PD-L1 H score terciles | >.9 | |||
| 0, 190 | 3 (27) | 3 (38) | 2 (20) | |
| 190, 240 | 4 (36) | 2 (25) | 4 (40) | |
| 240, 300 | 4 (36) | 3 (38) | 4 (40) | |
| Missing | 0 | 0 | 1 | |
| PD-L2 H score | 20.0 (0.0-135.0) | 30.0 (0.0-180.0) | 15.0 (0.0-60.0) | .4 |
| Missing | 0 | 0 | 1 | |
| PD-L2 H score terciles | .4 | |||
| 0, 10 | 1 (9.1) | 3 (38) | 4 (40) | |
| 10, 50 | 5 (45) | 1 (12) | 2 (20) | |
| 50, 200 | 5 (45) | 4 (50) | 4 (40) | |
| Missing | 0 | 0 | 1 | |
| STAT3 H score | 300.0 (140.0-300.0) | 300.0 (60.0-300.0) | 250.0 (70.0-300.0) | .5 |
| Missing | 0 | 0 | 1 |
| . | PMR∗, N = 11†,‡ . | Near-CMR§, N = 8† . | CMR‖, N = 11† . | P value¶ . |
|---|---|---|---|---|
| Stage | .6 | |||
| Early | 5 (45) | 4 (50) | 3 (27) | |
| Advanced | 6 (55) | 4 (50) | 8 (73) | |
| Epstein-Barr virus–encoded small RNAs | .3 | |||
| Negative | 7 (88) | 5 (83) | 4 (50) | |
| Positive | 1 (12) | 1 (17) | 4 (50) | |
| Missing | 3 | 2 | 3 | |
| 9p24.1 Alterations | .4 | |||
| Polysomy or copy gain | 4 (36) | 5 (71) | 5 (50) | |
| Amplification by ratio# | 7 (64) | 2 (29) | 5 (50) | |
| Missing | 0 | 1 | 1 | |
| Percent of residual disomic HRS cells | 0.0 (0.0-0.4) | 0.1 (0.0-0.9) | 0.0 (0.0-0.5) | .4 |
| Missing | 0 | 1 | 1 | |
| Percent of HRS cells with polysomy or CNG | 0.8 (0.2-1.0) | 0.9 (0.1-1.0) | 0.9 (0.5-1.0) | .9 |
| Missing | 0 | 1 | 1 | |
| Percent of HRS cells with amplification by ratio# | 0.0 (0.0-0.8) | 0.0 (0.0-0.1) | 0.0 (0.0-0.3) | .3 |
| Missing | 0 | 1 | 1 | |
| PD-L1 H score | 213.0 (122.0-300.0) | 211.5 (20.0-300.0) | 221.5 (62.0-300.0) | >.9 |
| Missing | 0 | 0 | 1 | |
| PD-L1 H score terciles | >.9 | |||
| 0, 190 | 3 (27) | 3 (38) | 2 (20) | |
| 190, 240 | 4 (36) | 2 (25) | 4 (40) | |
| 240, 300 | 4 (36) | 3 (38) | 4 (40) | |
| Missing | 0 | 0 | 1 | |
| PD-L2 H score | 20.0 (0.0-135.0) | 30.0 (0.0-180.0) | 15.0 (0.0-60.0) | .4 |
| Missing | 0 | 0 | 1 | |
| PD-L2 H score terciles | .4 | |||
| 0, 10 | 1 (9.1) | 3 (38) | 4 (40) | |
| 10, 50 | 5 (45) | 1 (12) | 2 (20) | |
| 50, 200 | 5 (45) | 4 (50) | 4 (40) | |
| Missing | 0 | 0 | 1 | |
| STAT3 H score | 300.0 (140.0-300.0) | 300.0 (60.0-300.0) | 250.0 (70.0-300.0) | .5 |
| Missing | 0 | 0 | 1 |
PMR is defined as >50% but <90% reduction in MTV.
n (%) or median (minimum-maximum).
Includes 1 patient with an indeterminate response according to the Lymphoma Response to Immunomodulatory Therapy Criteria.
Near-CMR defined as ≥90% reduction in MTV, but less than CMR by Lugano 2014 criteria.
CMR per Lugano 2014 criteria.
Fisher exact test and Kruskal-Wallis rank-sum test.
Amplification defined as a target to probe ratio > 3:1.